CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | aldose phosphate |
|
Accession: | CHEBI:35131
|
browse the term
|
Synonyms: | related_synonym: | aldose phosphates |
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Deoxycytidine Monophosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 2'-deoxyguanosine 5'-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein |
CTD |
PMID:20339114 PMID:20655299 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport multiple interactions affects uptake |
ISO |
ABCC4 protein results in increased transport of Cyclic AMP Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog] |
CTD |
PMID:11856762 PMID:28587784 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases abundance |
ISO |
ADIPOQ protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18931039 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases abundance |
EXP |
ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP] ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP |
CTD |
PMID:10374718 PMID:17306419 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:12649302 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases abundance affects abundance |
ISO EXP |
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:17200720 PMID:18378355 PMID:18787115 PMID:19419905 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases chemical synthesis increases abundance affects abundance |
EXP ISO |
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP [Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP] ADRB2 protein results in increased abundance of Cyclic AMP ADRB2 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 PMID:14730417 PMID:16036225 PMID:16980553 PMID:17925438 PMID:18378355 PMID:19419905 PMID:21868359 PMID:27825928 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions affects abundance |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP ADRB3 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10952688 PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression |
EXP ISO |
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA Cyclic AMP results in decreased expression of AHR protein |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA |
CTD |
PMID:16036225 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ank2 |
ankyrin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein |
CTD |
PMID:15536076 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:12859982 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein |
CTD |
PMID:25191754 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf5 |
activating transcription factor 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions increases abundance |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP AVPR2 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 PMID:33638691 |
|
NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
increases activity multiple interactions |
ISO EXP |
Cyclic AMP results in increased activity of BRAF protein [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein |
CTD |
PMID:21693435 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
C13h1orf115 |
similar to human chromosome 1 open reading frame 115 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C13H1ORF115 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068
|
|
G |
C1qtnf5 |
C1q and TNF related 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases abundance multiple interactions |
ISO EXP |
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]] Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
multiple interactions increases phosphorylation |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP ISO |
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] |
CTD |
PMID:21693435 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3E protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3G protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] |
CTD |
PMID:21693435 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases response to substance |
ISO |
CEBPB protein results in increased susceptibility to Cyclic AMP |
CTD |
PMID:23097472 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO EXP |
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides] CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] Cyclic AMP results in increased activity of CFTR protein Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form] |
CTD |
PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 PMID:15371258 More...
|
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions affects secretion increases abundance |
EXP ISO |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA CGA protein affects the secretion of Cyclic AMP CGA protein results in increased abundance of Cyclic AMP [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 PMID:31132478 PMID:33638691 PMID:37552060 More...
|
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:17558435 PMID:27429655 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:22676303 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:20360387 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO EXP |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:2153673 PMID:20702571 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:20702571 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CSF3 protein |
CTD |
PMID:7540958 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] |
CTD |
PMID:1699227 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Cstb |
cystatin B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP11A1 mRNA Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:25576683 PMID:28668616 PMID:29228121 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22172629 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein Cyclic AMP results in increased expression of CYP17A1 mRNA |
CTD |
PMID:23084589 PMID:25576683 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:29228121 PMID:31953017 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CYP51 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression decreases activity |
EXP |
Cyclic AMP results in decreased expression of CYP7B1 mRNA Cyclic AMP results in decreased activity of CYP7B1 protein |
CTD |
PMID:12029625 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dap |
death-associated protein |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 |
|
NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
affects response to substance |
ISO |
DKK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases abundance |
EXP |
DLD protein results in increased abundance of Cyclic AMP |
CTD |
PMID:25981801 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO EXP |
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP] [SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:8558425 PMID:15711596 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 PMID:17958328 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] |
CTD |
PMID:15542745 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA |
CTD |
PMID:12767924 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ehd2 |
EH-domain containing 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Cyclic AMP results in increased expression of EPO protein |
CTD |
PMID:18621143 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
EXP |
Cyclic AMP results in increased expression of ERRFI1 mRNA |
CTD |
PMID:1472065 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:19766106 PMID:20360387 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] |
CTD |
PMID:11804840 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:15,826,864...15,885,423
Ensembl chr12:15,826,871...15,884,543
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions increases expression |
ISO |
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] |
CTD |
PMID:28668616 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fig4 |
FIG4 phosphoinositide 5-phosphatase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA Cyclic AMP results in increased expression of FOS mRNA |
CTD |
PMID:10064622 PMID:10711420 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 PMID:31953017 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases abundance increases secretion |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP] FSHB protein results in increased secretion of Cyclic AMP NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 PMID:26895433 More...
|
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:26895433 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fzd10 |
frizzled class receptor 10 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP ISO |
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] [Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein] |
CTD |
PMID:22676303 PMID:26847930 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:113,879,972...113,924,742
Ensembl chr 3:113,879,973...113,923,696
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcg |
glucagon |
multiple interactions increases chemical synthesis increases abundance |
ISO EXP |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP GCG protein results in increased chemical synthesis of Cyclic AMP Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP] [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:19647008 PMID:33713149 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
ISO |
[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:22308467 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503
|
|
G |
Gipr |
gastric inhibitory polypeptide receptor |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr 1:78,804,287...78,814,462
Ensembl chr 1:78,805,593...78,814,462
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:58,170,417...58,202,258
Ensembl chr 5:58,170,425...58,202,272
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:18669601 PMID:25191754 |
|
NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
ISO |
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:20713914 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnal |
G protein subunit alpha L |
multiple interactions |
ISO |
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:11895442 PMID:15598656 PMID:23022524 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:17963371 PMID:23022524 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Greb1l |
GREB1 like retinoic acid receptor coactivator |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:1,392,330...1,629,483
Ensembl chr18:1,392,725...1,628,067
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] |
CTD |
PMID:25191754 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Grn |
granulin precursor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] |
CTD |
PMID:20056751 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241
|
|
G |
Gypc |
glycophorin C |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions decreases abundance |
ISO |
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] HCAR2 protein results in decreased abundance of Cyclic AMP |
CTD |
PMID:17124637 PMID:19223991 PMID:20655299 |
|
NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac6 |
histone deacetylase 6 |
affects abundance |
ISO |
HDAC6 protein affects the abundance of Cyclic AMP |
CTD |
PMID:28887310 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:183,780,583...183,783,030
|
|
G |
Hivep2 |
HIVEP zinc finger 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] |
CTD |
PMID:18602936 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hoxb1 |
homeo box B1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hp |
haptoglobin |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] |
CTD |
PMID:2419744 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hrh2 |
histamine receptor H 2 |
increases abundance multiple interactions |
ISO |
HRH2 protein results in increased abundance of Cyclic AMP [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 PMID:9681472 PMID:15843518 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
EXP |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B2 mRNA |
CTD |
PMID:18490834 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases abundance multiple interactions |
ISO |
HTR6 protein results in increased abundance of Cyclic AMP Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:11406289 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
increases abundance multiple interactions |
ISO |
HTR7 results in increased abundance of Cyclic AMP [3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] |
CTD |
PMID:10720076 PMID:14578406 PMID:19509219 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein |
CTD |
PMID:32781018 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions affects response to substance |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA] IER3 protein affects the susceptibility to Cyclic AMP [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19414516 PMID:20713914 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] |
CTD |
PMID:32781018 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] |
CTD |
PMID:15843518 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] |
CTD |
PMID:15843518 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
multiple interactions decreases expression |
ISO |
[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278
|
|
G |
Il17re |
interleukin 17 receptor E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:146,604,547...146,618,206
Ensembl chr 4:146,605,526...146,618,206
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA] |
CTD |
PMID:8904084 PMID:17709599 PMID:22117073 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il4 |
interleukin 4 |
increases chemical synthesis multiple interactions |
ISO |
IL4 protein results in increased chemical synthesis of Cyclic AMP Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:12230500 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Cyclic AMP analog results in increased expression of IL6 mRNA |
CTD |
PMID:10469353 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
increases secretion |
ISO |
Cyclic AMP results in increased secretion of INHBA protein |
CTD |
PMID:20074812 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
[Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] |
CTD |
PMID:4306506 PMID:26847930 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Irf6 |
interferon regulatory factor 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kng1 |
kininogen 1 |
increases abundance |
EXP |
KNG1 results in increased abundance of Cyclic AMP |
CTD |
PMID:15750287 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
increases abundance multiple interactions increases expression |
ISO |
LEP protein results in increased abundance of Cyclic AMP 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA] |
CTD |
PMID:11342529 PMID:27381457 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions increases abundance increases chemical synthesis affects secretion |
EXP ISO |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP] CGB3 protein results in increased chemical synthesis of Cyclic AMP; LHB protein results in increased chemical synthesis of Cyclic AMP LHB protein affects the secretion of Cyclic AMP [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases activity |
ISO |
Cyclic AMP results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lurap1l |
leucine rich adaptor protein 1-like |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein |
CTD |
PMID:33713149 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA |
CTD |
PMID:23084589 |
|
NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Msantd3 |
Myb/SANT DNA binding domain containing 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:62,866,022...62,892,444
Ensembl chr 5:62,866,022...62,888,859
|
|
G |
Ndufb11 |
NADH:ubiquinone oxidoreductase subunit B11 |
increases phosphorylation multiple interactions |
ISO |
Cyclic AMP results in increased phosphorylation of NDUFB11 protein Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] |
CTD |
PMID:17904600 |
|
NCBI chr X:1,572,805...1,575,063
Ensembl chr X:1,572,785...1,575,062
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Cyclic AMP results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:23137853 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of NR0B1 mRNA Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:19822634 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Ntan1 |
N-terminal asparagine amidase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:2,111,090...2,126,119
|
|
G |
Oat |
ornithine aminotransferase |
increases activity multiple interactions increases expression |
EXP |
Cyclic AMP results in increased activity of OAT protein Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2824512 PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP |
CTD |
PMID:11413242 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Or51a41 |
olfactory receptor family 51 subfamily A member 41 |
multiple interactions |
ISO |
[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15598656 |
|
NCBI chr 1:157,454,391...157,455,398
Ensembl chr 1:157,454,041...157,456,953
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:12767924 PMID:15716417 |
|
NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858 Ensembl chr 3:73,516,364...73,519,858
|
|
G |
Or6e1 |
olfactory receptor family 6 subfamily E member 1 |
multiple interactions |
ISO |
[citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr15:27,733,881...27,734,825
Ensembl chr15:27,729,827...27,736,945
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Cyclic AMP results in increased expression of PCK1 mRNA [Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] |
CTD |
PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 PMID:26847930 More...
|
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde11a |
phosphodiesterase 11A |
increases hydrolysis |
ISO |
PDE11A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:10725373 |
|
NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP [Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 PMID:21266552 PMID:21854221 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde7a |
phosphodiesterase 7A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 |
|
NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
|
|
G |
Pde7b |
phosphodiesterase 7B |
increases hydrolysis multiple interactions |
ISO |
PDE7B protein results in increased hydrolysis of Cyclic AMP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 PMID:10872825 |
|
NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
|
|
G |
Pde8a |
phosphodiesterase 8A |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] PDE8A protein results in increased hydrolysis of Cyclic AMP Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:9671792 PMID:12681444 |
|
NCBI chr 1:135,166,143...135,288,986
Ensembl chr 1:135,166,237...135,288,024
|
|
G |
Pde8b |
phosphodiesterase 8B |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] |
CTD |
PMID:9784418 PMID:12681444 |
|
NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:9624146 |
|
NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects abundance |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:26670611 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pfn2 |
profilin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:142,067,102...142,072,938
Ensembl chr 2:142,067,104...142,072,938
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:37552060 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein] |
CTD |
PMID:22187434 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP ISO |
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] POMC protein modified form results in increased abundance of Cyclic AMP Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 PMID:26586997 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
Cyclic AMP results in increased expression of POR mRNA |
CTD |
PMID:25576683 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] Cyclic AMP results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18602936 PMID:22117073 PMID:22676303 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions affects response to substance |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] |
CTD |
PMID:11907174 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] |
CTD |
PMID:11907174 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion |
EXP ISO |
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA] Cyclic AMP results in increased secretion of PRL protein |
CTD |
PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prok1 |
prokineticin 1 |
affects response to substance |
ISO |
PROK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:15563582 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:10357836 |
|
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgir |
prostaglandin I2 receptor |
multiple interactions |
ISO |
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11895442 |
|
NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] |
CTD |
PMID:21873648 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
increases abundance |
EXP |
PTH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:26851681 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
increases abundance |
ISO |
PTHLH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:10600786 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptma |
prothymosin alpha |
increases abundance |
ISO |
PTMA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:9147362 |
|
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Ralgdsl1 |
ral guanine nucleotide dissociation stimulator like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity |
ISO |
Cyclic AMP results in increased activity of RAP1A protein |
CTD |
PMID:24701590 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] |
CTD |
PMID:21693435 |
|
NCBI chr 7:53,423,039...53,456,349
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rbfox3 |
RNA binding fox-1 homolog 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein |
CTD |
PMID:33713149 |
|
NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935
|
|
G |
Rbm12 |
RNA binding motif protein 12 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:144,609,661...144,629,911
Ensembl chr 3:144,611,623...144,629,915 Ensembl chr 3:144,611,623...144,629,915
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein |
CTD |
PMID:33713149 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scn2a |
sodium voltage-gated channel alpha subunit 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214
|
|
G |
Sct |
secretin |
multiple interactions increases abundance |
EXP |
Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:6312992 |
|
NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658
|
|
G |
Sdc1 |
syndecan 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein |
CTD |
PMID:33713149 |
|
NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
affects transport |
ISO |
SLC22A8 protein affects the transport of Cyclic AMP |
CTD |
PMID:11306713 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
affects expression multiple interactions |
ISO EXP |
Cyclic AMP affects the expression of SLC2A5 mRNA [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein [Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:8554516 PMID:12820898 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] |
CTD |
PMID:12612912 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Smoc2 |
SPARC related modular calcium binding 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693
|
|
G |
Snx33 |
sorting nexin 33 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:23782265 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] |
CTD |
PMID:20685861 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of SRD5A1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351
|
|
G |
St6gal2 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:9,181,744...9,274,161
Ensembl chr 9:9,182,399...9,269,697
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO |
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein |
CTD |
PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions |
ISO |
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084
|
|
G |
Tas1r2 |
taste 1 receptor member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:151,909,617...151,925,760
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Tax1bp1 |
Tax1 binding protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:81,821,991...81,877,906
Ensembl chr 4:81,821,989...81,879,100
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tex14 |
testis expressed 14, intercellular bridge forming factor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:72,231,766...72,356,938
Ensembl chr10:72,231,801...72,355,805
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tmsb15b2 |
thymosin beta 15B2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:100,298,705...100,300,820
Ensembl chr X:100,298,514...100,300,886
|
|
G |
Tmtc4 |
transmembrane O-mannosyltransferase targeting cadherins 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:100,000,157...100,056,573
Ensembl chr15:100,000,152...100,056,543
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of TNF protein Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:8550079 PMID:21266552 PMID:23566200 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf12 |
TNF superfamily member 12 |
decreases expression |
ISO |
Cyclic AMP results in decreased expression of TNFSF12 mRNA |
CTD |
PMID:22117073 |
|
NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein] |
CTD |
PMID:22187434 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions increases abundance |
ISO |
[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21072367 PMID:21123444 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions increases abundance |
ISO |
[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21123444 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Ttc6 |
tetratricopeptide repeat domain 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:75,136,827...75,368,176
Ensembl chr 6:75,136,792...75,368,178
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Uba5 |
ubiquitin-like modifier activating enzyme 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894
|
|
G |
Vash1 |
vasohibin 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:106,330,374...106,345,740
Ensembl chr 6:106,329,123...106,345,726
|
|
G |
Vash2 |
vasohibin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391
|
|
G |
Vat1 |
vesicle amine transport 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:86,389,549...86,397,167
Ensembl chr10:86,389,545...86,397,224
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions increases abundance |
ISO EXP |
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP] VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP |
CTD |
PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 6:136,996,664...137,070,599
Ensembl chr 6:137,001,511...137,070,597
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] |
CTD |
PMID:20685861 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases abundance |
ISO |
ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP |
CTD |
PMID:24830504 |
|
NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases export increases transport multiple interactions |
ISO |
ABCC4 protein results in increased export of Cyclic GMP ABCC4 protein results in increased transport of Cyclic GMP daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] |
CTD |
PMID:11856762 PMID:16156793 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases abundance |
EXP |
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] AGT protein modified form results in increased abundance of Cyclic GMP |
CTD |
PMID:11696475 PMID:28299329 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] |
CTD |
PMID:12891555 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] |
CTD |
PMID:17585900 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Apoe |
apolipoprotein E |
decreases abundance |
ISO |
APOE gene mutant form results in decreased abundance of Cyclic GMP |
CTD |
PMID:11397713 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
EXP |
[bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] |
CTD |
PMID:9388267 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:25490417 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
multiple interactions |
ISO |
CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] |
CTD |
PMID:24213632 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] |
CTD |
PMID:25041251 PMID:25490417 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
affects abundance increases abundance multiple interactions |
ISO |
GCH1 protein affects the abundance of Cyclic GMP GCH1 gene mutant form results in increased abundance of Cyclic GMP CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:21963838 PMID:25490417 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
[manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein |
CTD |
PMID:17110411 PMID:17290048 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions increases abundance |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP |
CTD |
PMID:22171090 PMID:24213632 PMID:25373139 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP |
CTD |
PMID:22171090 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects abundance |
ISO |
HMOX2 affects the abundance of Cyclic GMP |
CTD |
PMID:16181104 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
increases expression |
ISO |
Cyclic GMP results in increased expression of IL12RB2 mRNA |
CTD |
PMID:12451176 |
|
NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
EXP ISO |
Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP] |
CTD |
PMID:11506125 PMID:14762100 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] Cyclic GMP results in decreased phosphorylation of MAP2K1 protein |
CTD |
PMID:18225537 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases phosphorylation multiple interactions |
ISO |
Cyclic GMP results in decreased phosphorylation of MAP2K2 protein Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] |
CTD |
PMID:18225537 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Cyclic GMP analog results in increased activity of MAPK8 protein |
CTD |
PMID:11051267 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP |
CTD |
PMID:20463352 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases abundance |
ISO EXP |
NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP] NOS3 protein results in increased abundance of Cyclic GMP |
CTD |
PMID:11504159 PMID:16891913 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases abundance |
ISO EXP |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] NPPA protein results in increased abundance of Cyclic GMP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] |
CTD |
PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 PMID:18225537 More...
|
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppc |
natriuretic peptide C |
increases chemical synthesis increases abundance multiple interactions |
EXP |
NPPC protein results in increased chemical synthesis of Cyclic GMP NPPC protein results in increased abundance of Cyclic GMP Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:17629948 PMID:18222015 |
|
NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde11a |
phosphodiesterase 11A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10725373 |
|
NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde1a |
phosphodiesterase 1A |
multiple interactions |
EXP |
PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] |
CTD |
PMID:11696475 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases abundance |
ISO |
PDE5A protein results in decreased abundance of Cyclic GMP |
CTD |
PMID:10422958 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis multiple interactions |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic GMP zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:9624146 |
|
NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pomc |
proopiomelanocortin |
affects abundance |
EXP |
POMC protein affects the abundance of Cyclic GMP |
CTD |
PMID:11193135 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ptpn12 |
protein tyrosine phosphatase, non-receptor type 12 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PTPN12 protein |
CTD |
PMID:12714323 |
|
NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] |
CTD |
PMID:21145922 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases abundance |
EXP |
7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] |
CTD |
PMID:16754782 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases abundance |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:18575783 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] |
CTD |
PMID:11588525 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] |
CTD |
PMID:17339839 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] |
CTD |
PMID:35101544 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions increases sulfation |
ISO |
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate |
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
affects binding multiple interactions |
ISO |
7-methylguanosine 5'-diphosphate analog binds to EIF4E protein 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] |
CTD |
PMID:16415093 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression increases response to substance |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP |
CTD |
PMID:14996839 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein |
CTD |
PMID:14996839 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cfl1 |
cofilin 1 |
decreases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form |
CTD |
PMID:15163550 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein |
CTD |
PMID:14741741 PMID:20610540 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Acetylcysteine results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] which results in increased cleavage of PARP1 protein |
CTD |
PMID:38042493 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein |
CTD |
PMID:20610540 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rtkn |
rhotekin |
multiple interactions |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] |
CTD |
PMID:20610540 |
|
NCBI chr 4:115,640,813...115,657,952
Ensembl chr 4:115,640,774...115,657,952
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions affects splicing |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vip |
vasoactive intestinal peptide |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA |
CTD |
PMID:2156696 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein |
CTD |
PMID:16166323 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Arhgef17 |
Rho guanine nucleotide exchange factor 17 |
multiple interactions |
ISO |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] |
CTD |
PMID:23195829 |
|
NCBI chr 1:155,230,607...155,290,163
Ensembl chr 1:155,233,168...155,290,498
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein] |
CTD |
PMID:20471953 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein] |
CTD |
PMID:20471953 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11799084 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein] |
CTD |
PMID:20471953 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions decreases expression increases activity |
ISO EXP |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:9366573 PMID:11799084 PMID:23195829 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein] |
CTD |
PMID:23195829 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation decreases phosphorylation |
ISO EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein |
CTD |
PMID:11799084 PMID:16166323 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein |
CTD |
PMID:17478430 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:30610963 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:74,865,409...74,990,334
Ensembl chr14:74,866,281...74,990,334
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acp3 |
acid phosphatase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Adamts6 |
ADAM metallopeptidase with thrombospondin type 1 motif, 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298
|
|
G |
Adamts8 |
ADAM metallopeptidase with thrombospondin type 1 motif, 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:29,349,078...29,368,413
Ensembl chr 8:29,349,114...29,368,404
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adgrd1 |
adhesion G protein-coupled receptor D1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:27,488,908...27,603,714
Ensembl chr12:27,488,908...27,603,696
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:68,963,186...68,981,649
Ensembl chr13:68,962,991...68,992,570
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aopep |
aminopeptidase O |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:1,811,281...2,127,316
Ensembl chr17:1,811,980...2,127,331
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apbb1ip |
amyloid beta precursor protein binding family B member 1 interacting protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:84,941,404...85,033,020
Ensembl chr17:84,982,243...85,033,010
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcdd1 |
APC down-regulated 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:56,385,398...56,416,065
Ensembl chr18:56,385,264...56,416,070
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Armcx3 |
armadillo repeat containing, X-linked 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:97,937,115...97,942,098
Ensembl chr X:97,936,999...97,942,098
|
|
G |
Armcx4 |
armadillo repeat containing, X-linked 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:97,860,526...97,870,912
Ensembl chr X:97,860,629...97,870,912
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:153,409,019...153,509,019
Ensembl chr 4:153,409,004...153,509,321
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein |
CTD |
PMID:11802967 PMID:16709600 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 |
CTD |
PMID:11802967 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein |
CTD |
PMID:16709600 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brinp1 |
BMP/retinoic acid inducible neural specific 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:82,348,501...82,550,506
Ensembl chr 5:82,348,930...82,493,150
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:8,286,337...8,645,567
Ensembl chr20:8,288,711...8,643,960
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:3,076,556...3,181,181
Ensembl chr18:3,075,524...3,181,181
|
|
G |
Cabp7 |
calcium binding protein 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:79,598,822...79,609,172
Ensembl chr14:79,598,827...79,609,240
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400
|
|
G |
Caln1 |
calneuron 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:25,811,743...26,303,670
Ensembl chr12:25,819,628...26,303,344
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capn6 |
calpain 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:107,380,774...107,405,489
Ensembl chr X:107,380,774...107,405,489
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:104,572,059...104,601,606
Ensembl chr10:104,566,424...104,601,905
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA |
CTD |
PMID:16709600 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:40,945,607...41,050,010
Ensembl chr 1:40,945,961...41,085,040
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:73,031,891...73,135,173
Ensembl chr17:73,035,045...73,135,337
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein |
CTD |
PMID:11230753 PMID:16997883 PMID:20940016 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccn6 |
cellular communication network factor 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:42,569,309...42,585,126
Ensembl chr20:42,569,309...42,585,126
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd244 |
CD244 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:84,051,339...84,082,864
Ensembl chr13:84,052,493...84,074,492
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein |
CTD |
PMID:32028606 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh22 |
cadherin 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:153,845,563...153,970,630
Ensembl chr 3:153,845,787...153,970,588
|
|
G |
Cdh4 |
cadherin 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:166,525,092...167,003,380
Ensembl chr 3:166,525,099...167,003,371
|
|
G |
Cdh6 |
cadherin 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cdx1 |
caudal type homeo box 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:54,472,587...54,490,913
Ensembl chr18:54,473,444...54,490,814
|
|
G |
Ceacam6 |
CEA cell adhesion molecule 6 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form |
CTD |
PMID:16709600 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA |
CTD |
PMID:8404651 PMID:21467749 PMID:22079614 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cgn |
cingulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chp1 |
calcineurin-like EF-hand protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:106,536,009...106,571,255
Ensembl chr 3:106,536,004...106,571,251
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:23,079,918...23,110,518
Ensembl chr 2:23,079,918...23,110,430
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clic3 |
chloride intracellular channel 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:42,974,462...43,027,321
Ensembl chr12:42,974,410...43,028,129
|
|
G |
Cnih3 |
cornichon family AMPA receptor auxiliary protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:93,016,707...93,208,168
Ensembl chr13:93,099,784...93,208,121
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
|
|
G |
Coro2a |
coronin 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:53,225,647...53,286,220
Ensembl chr 7:53,225,696...53,286,220
|
|
G |
Cpo |
carboxypeptidase O |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:65,319,996...65,338,250
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:29,940,240...29,952,907
Ensembl chr 7:29,798,586...29,952,907
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18467523 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] |
CTD |
PMID:2153673 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:202,655,322...202,657,030
Ensembl chr 1:202,655,322...202,657,030
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:109,294,249...110,443,409
Ensembl chr 4:109,293,978...110,443,522
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:46,800,975...46,964,681
Ensembl chr 4:46,800,981...46,964,631
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:34,507,723...34,707,581
Ensembl chr12:34,520,959...34,705,806
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA |
CTD |
PMID:20711499 PMID:22079614 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO EXP |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein] |
CTD |
PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 PMID:22546480 PMID:24014645 PMID:24328340 PMID:24740604 PMID:34896276 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions increases expression |
ISO |
bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA]; Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22079614 PMID:22172629 PMID:22546480 PMID:34896276 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA |
CTD |
PMID:21610156 PMID:22079614 PMID:34896276 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 PMID:24014645 PMID:34896276 More...
|
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
EXP ISO |
[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein |
CTD |
PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 PMID:23583632 PMID:28859905 PMID:30951242 More...
|
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 PMID:22079614 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:78,718,963...79,018,023
Ensembl chr X:78,451,593...79,017,592
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:123,695,286...123,698,905
Ensembl chr X:123,695,286...123,698,905
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:42,125,525...42,179,927
Ensembl chr11:42,125,787...42,179,697
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
multiple interactions |
ISO |
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases activity |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]] |
CTD |
PMID:11425850 PMID:18420745 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:78,937,788...79,255,551
Ensembl chr 2:78,937,800...79,254,890
|
|
G |
Dnajb3 |
DnaJ heat shock protein family (Hsp40) member B3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:88,795,542...88,796,555
Ensembl chr 9:88,795,488...88,796,560
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:112,932,736...112,934,050
Ensembl chr 7:112,932,616...112,945,537
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dock11 |
dedicator of cytokinesis 11 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:115,131,720...115,314,854
Ensembl chr X:115,131,909...115,314,854
|
|
G |
Dok5 |
docking protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:18467523 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:71,453,338...71,505,833
Ensembl chr 5:71,456,310...71,505,762
|
|
G |
Emp2 |
epithelial membrane protein 2 |
multiple interactions decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epg5 |
ectopic P-granules 5 autophagy tethering factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:71,403,990...71,502,079
Ensembl chr18:71,404,010...71,501,502
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erf |
Ets2 repressor factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:80,829,935...80,838,388
Ensembl chr 1:80,829,935...80,838,388
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA |
CTD |
PMID:23166782 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Esrrg |
estrogen-related receptor gamma |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] |
CTD |
PMID:21903722 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein |
CTD |
PMID:16709600 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA |
CTD |
PMID:15774544 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein] |
CTD |
PMID:24740604 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fer1l6 |
fer-1-like family member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:90,093,567...90,216,907
Ensembl chr 7:90,061,924...90,215,214
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF10 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FGF13 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FHL2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Flot1 |
flotillin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Flot2 |
flotillin 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FLOT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein] |
CTD |
PMID:16709600 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA] |
CTD |
PMID:16709600 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxr1 |
forkhead box R1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FOXR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:44,760,587...44,768,696
Ensembl chr 8:44,760,948...44,768,880
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FRAS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:12,791,407...13,200,862
Ensembl chr14:12,793,599...13,200,726
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA] |
CTD |
PMID:8404651 PMID:10746652 PMID:21467749 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fzd10 |
frizzled class receptor 10 |
increases expression |
ISO |
8- | |